The Current Ratio as of November 2024 (TTM) for INmune Bio, Inc. (INMB) is 2.59

According to INmune Bio, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.59. This represents a change of 17.57% compared to the average of 2.21 of the last 4 quarters.

INmune Bio, Inc. (INMB) Historical Current Ratio (quarterly & annually)

How has INMB Current Ratio performed in the past?

The mean historical Current Ratio of INmune Bio, Inc. over the last ten years is 6.66. The current 2.59 Current Ratio has changed 3.79% with respect to the historical average. Over the past ten years (40 quarters), INMB's Current Ratio was at its highest in in the June 2022 quarter at 30.87. The Current Ratio was at its lowest in in the September 2016 quarter at 0.

INmune Bio, Inc. (INMB) Current Ratio by Quarter and Year

Discovering the peaks and valleys of INmune Bio, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

INmune Bio, Inc. (INMB) Average Current Ratio

How has INMB Current Ratio performed in the past?

The current Current Ratio of INmune Bio, Inc. (INMB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

INmune Bio, Inc. (INMB) Current Ratio vs. Peers

How is INMB’s Current Ratio compared to its peers?

INmune Bio, Inc.’s Current Ratio is greater than TFF Pharmaceuticals, Inc. (0.89), less than Anebulo Pharmaceuticals, Inc. (3.45), greater than Abcam plc (1.27), less than AN2 Therapeutics, Inc. (9.75), greater than Cue Biopharma, Inc. (2.22), less than Anixa Biosciences, Inc. (11.31), greater than IN8bio, Inc. (1.84), greater than PolyPid Ltd. (1.00), less than Aerovate Therapeutics, Inc. (8.78), less than Eliem Therapeutics, Inc. (60.41), less than Decibel Therapeutics, Inc. (4.81), less than Anavex Life Sciences Corp. (12.04), less than Cassava Sciences, Inc. (3.55), less than BioVie Inc. (2.95), greater than Cognition Therapeutics, Inc. (2.11), less than TScan Therapeutics, Inc. (9.56), less than Dermata Therapeutics, Inc. (7.11),

Build a custom stock screener for INmune Bio, Inc. (INMB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like INmune Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

INmune Bio, Inc. (INMB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like INmune Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.